Rilpivirine: all 60 studies that test it

Page 1 of 1. Open to participants first (1), then studies with results posted, then the rest; newest registration first within each.

• Pharmacokinetics, Safety, Tolerability of Dolutegravir/Rilpivirine in PediatricsRecruitingNCT05674656Phase 1/2
• A Sub-study of Cabotegravir (CAB) and Rilpivirine (RPV) in Human Immunodeficiency Viruses (HIV)-Infected ParticipantsCompletedNCT05896761Phase 3Results posted
• Study to Assess the Effects of Cabotegravir (CAB) and Rilpivirine (RPV) Long-Acting (LA) Injections Following Sub-cutaneous (SC) Administration Compared With Intramuscular (IM) Administration in Adult Participants Living With Human Immunodeficiency Virus (HIV-1) Infection in the FLAIR StudyCompletedNCT05896748Phase 3Results posted
• A Study to Evaluate Efficacy and Safety of Cabotegravir (CAB) Long Acting (LA) Plus (+) Rilpivirine (RPV) LA Versus BIKTARVY® (BIK) in Participants With Human Immunodeficiency Virus (HIV)-1 Who Are Virologically SuppressedCompletedNCT04542070Phase 3Results posted
• Pharmacokinetic Study of Cabotegravir and Rilpivirine Long-acting Intramuscular Injections in Healthy Adult ParticipantsCompletedNCT04371380Phase 1Results posted
• A Study of Switching to RPV Plus Other ARVs in HIV-1-infected Children (Aged 2 to <12 Years) Who Are Virologically SuppressedCompletedNCT04012931Phase 2Results posted
• The LATITUDE Study: Long-Acting Therapy to Improve Treatment SUccess in Daily LifECompletedNCT03635788Phase 3Results posted
• More Options for Children and Adolescents (MOCHA): Oral and Long-Acting Injectable Cabotegravir and Rilpivirine in HIV-Infected Children and AdolescentsCompletedNCT03497676Phase 1/2Results posted
• Efficacy, Safety and Tolerability Study of Long-acting Cabotegravir Plus Long-acting Rilpivirine (CAB LA + RPV LA) in Human-immunodeficiency Virus-1 (HIV-1) Infected AdultsActive, not recruitingNCT03299049Phase 3Results posted
• Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current Antiretroviral Regimen in Virologically Suppressed HIV-1-infected AdultsActive, not recruitingNCT02951052Phase 3Results posted
• Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive ParticipantsActive, not recruitingNCT02938520Phase 3Results posted
• Phase II Safety and Acceptability of an Investigational Injectable Product, TMC278LA, for Pre-Exposure ProphylaxisCompletedNCT02165202Phase 2Results posted
• FTC/RPV/TDF on T-Cell Activation, CD4+ T-Cell Count, Inflammatory Biomarkers and Viral ReservoirCompletedNCT01777997Phase 4Results posted
• A Clinical Trial Comparing the Efficacy of Tenofovir Disoproxil Fumarate/Emtricitabine/Rilpivirine (TDF/FTC/RPV) Versus TDF/FTC/Efavirenz (TDF/FTC/EFV) in Patients With Undetectable Plasma HIV-1 RNA on Current First-line TreatmentCompletedNCT01709084Phase 3Results posted
• Dose Ranging Study of GSK1265744 Plus Nucleoside Reverse Transcriptase Inhibitors for Induction of Human Immunodeficiency Virus-1 (HIV-1) Virologic Suppression Followed by Virologic Suppression Maintenance by GSK1265744 Plus RilpivirineCompletedNCT01641809Phase 2Results posted
• Efavirenz Versus Rilpivirine on Vascular Function, Inflammation, and Oxidative StressCompletedNCT01585038Phase 4Results posted
• The Rilpivirine Cerebrospinal-fluid (CSF) StudyCompletedNCT01562886Phase 1Results posted
• A Trial With TMC278-TIDP6-C222 for Continued TMC278 Access in Patients Infected With Human Immunodeficiency Virus-1CompletedNCT01266902Phase 3Results posted
• A Single-arm, Open-label, Study to Assess the Pharmacokinetics of Darunavir and Ritonavir, Darunavir and Cobicistat, Etravirine, and Rilpivirine in HIV-1 Infected Pregnant WomenCompletedNCT00855335Phase 3Results posted
• A Study to Evaluate the Pharmacokinetics, Safety, Tolerability, and Antiviral Activity of Rilpivirine (TMC278) in Human Immunodeficiency Virus Infected Adolescents and Children Aged Greater Than or Equal to 6 YearsCompletedNCT00799864Phase 2Results posted
• TMC278-TiDP6-C215: A Clinical Trial in Treatment Naive HIV-subjects Patients Comparing TMC278 to Efavirenz in Combination With 2 Nucleoside/Nucleotide Reverse Transcriptase InhibitorsCompletedNCT00543725Phase 3Results posted
• TMC278-TiDP6-C209: A Clinical Trial in Treatment Naive HIV-1 Patients Comparing TMC278 to Efavirenz in Combination With Tenofovir + Emtricitabine.CompletedNCT00540449Phase 3Results posted
• A Study of TMC278 in Human Immunodeficiency Virus Type 1 Infected Patients, Who Are Not Treated With Antiretroviral MedicinesCompletedNCT00110305Phase 2Results posted
• A Clinical Study of the Interactions Between Azvudine Tablets (FNC) and Rilpivirine Tablets (RPV)CompletedNCT07001488Phase 1
• RPV+DRV/Cobi Dual Therapy in Subjects With HIV Controlled InfectionStatus unknownNCT04064632Phase 4
• Efficacy of Rilpivirine-based Regimens as Switch Therapy From Nevirapine-based Regimens in HIV-infected PatientsCompletedNCT03664440Not applicable
• Darunavir and Rilpivirine Interactions With Etonogestrel Contraceptive ImplantStatus unknownNCT03589040Phase 2
• Darunavir and Rilpivirine Interactions With Levonorgestrel ImplantStatus unknownNCT03589027Phase 2
• Neurocognitive Function Improvement After Switching From Efavirenz to RilpivirineStatus unknownNCT03567304Phase 4
• A Study to Determine the Safety and Efficacy of Rilpivirine in Treatment-naive Indian Participants With Human Immunodeficiency Virus Type 1 (HIV-1) InfectionTerminatedNCT03563742Phase 3
• Switching TDF/FTC/EFV to TDF/FTC/RPV VS Continuing TDF/FTC/EFV in HIV Patients With Complete Virological SuppressionCompletedNCT03251690Not applicable
• A Study to Investigate the Effect of Different Particle Sizes on the Single-dose Pharmacokinetics of Rilpivirine After Intramuscular Injection of a Long-acting Nanosuspension in Healthy ParticipantsCompletedNCT03127189Phase 1
• Rilpivirine in Virologically Suppressed AdolescentsStatus unknownNCT03033368Phase 2/3
• Relative Bioavailability of Three Oral Formulations Candidates of Rilpivirine for Potential Pediatric Use Compared to Oral TabletCompletedNCT02561936Phase 1
• A Study to Evaluate the Pharmacokinetics of Rilpivirine/Tenofovir/Emtricitabine After a Single-Oral Administration in Healthy Japanese Adult Male ParticipantsCompletedNCT02530060Phase 4
• A Roll-over Study With Rilpivirine for Human Immunodeficiency Virus Type 1 (HIV-1) Infected Participants Who Participated in Rilpivirine Pediatric StudiesActive, not recruitingNCT02494986Phase 2
• Decrease of Neuropsychiatric Side Effects After Switching From Atripla to EvipleraTerminatedNCT02447016Phase 4
• Open Label, Pilot Study of Darunavir Boosted by Cobicistat in Combination With Rilpivirine to Treat HIV+ Naïve SubjectsStatus unknownNCT02404233Phase 4
• Switch From Nevirapine-based Regimen to Once a Day Rilpivirine/Emtricitabine/TenofovirCompletedNCT02104700Phase 2/3
• Safety, Tolerability, Drug Interactions, and Antiviral Activity of Rilpivirine in Antiretroviral-Naive HIV-Infected Children Less Than 12 Years of AgeWithdrawnNCT01975012Phase 1/2
• A Single-Dose Pharmacokinetics and Safety Study of TMC278 in Healthy Adult Japanese ParticipantsCompletedNCT01804244Phase 4
• A Phase IV, Open-label Single-arm Study Investigating the Pharmacokinetics and Pharmacodynamics of the Antiretroviral Combination of Rilpivirine and Ritonavirboosted Darunavir in Therapy-naive HIV-1 Infected Patients.CompletedNCT01736761Phase 4
• A Study to Explore Pharmacokinetic Interaction Between Rilpivirine and Metformin in Healthy ParticipantsCompletedNCT01719614Phase 1
• A Pilot Study to Assess the Feasibility of Switching, Individuals Receiving Atripla With Continuing Central Nervous System (CNS) Toxicity, to a Fixed Dose Combination of Tenofovir/Emtricitabine/RilpivirineCompletedNCT01701882Phase 3
• A Study to Evaluate Safety, Acceptability, Pharmacokinetics, and ex Vivo Pharmacodynamics of TMC278 Long Acting Formulation in HIV-1 Seronegative ParticipantsCompletedNCT01656018Phase 1
• A Study to Explore the Pharmacokinetics of Rilpivirine With Rifabutin in Healthy ParticipantsCompletedNCT01615614Phase 1
• A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Repeat Dose Administration of Long-Acting GSK1265744 and Long-Acting TMC278 Intramuscular and Subcutaneous Injections in Healthy Adult SubjectsCompletedNCT01593046Phase 1
• A Study to Investigate the Effect of Steady-State TMC278 on the Pharmacokinetics of a Single Dose of DigoxinCompletedNCT01519128Phase 1
• TMC125IFD1001 - Drug-Drug Interaction of Etravirine With Telaprevir and TMC278 With Telaprevir.CompletedNCT01336829Phase 1
• TMC278-TiDP6-C153 - A Study in Healthy Volunteers Investigating the Pharmacokinetic Interaction Between TMC278 and RaltegravirCompletedNCT01288755Phase 1
• A Phase I, Open-label Trial to Explore the Pharmacokinetics, Safety and Tolerability of TMC278 (Rilpivirine) 25 mg Once Daily Following a 2-week Period Receiving Efavirenz, in Healthy Male and Female VolunteersCompletedNCT01268839Phase 1
• TMC435-TiDP16-C114 - A Study in Healthy Volunteers Investigating the Pharmacokinetic Interaction Between TMC435 and the Antiretroviral Agents TMC278 and TenofovirCompletedNCT01205139Phase 1
• Pre-Exposure Prophylaxis Using TMC278LATerminatedNCT01049932Phase 1/2
• TMC278-TiDP6-C154: Evaluation of the Possible Influence of Omeprazole Intake - and the pH Increase in the Stomach Triggered by Omeprazole Intake - on the Blood Levels of TMC278 in Healthy VolunteersCompletedNCT01001247Phase 1
• TMC278-TiDP38-C145: A Bioavailability Study in Healthy Adult Volunteers to Evaluate 3 Pediatric Formulations of TMC278 (a Solution, a Suspension, and Granules) Compared to an Adult Tablet FormulationCompletedNCT00812292Phase 1
• TMC278-TiDP6-C152: A Study to Assess the Effects of TMC278 and Efavirenz (EFV) on the QT/QTc Interval (Heart Conduction and Heart Rhythm) in Healthy Volunteers.CompletedNCT00744809Phase 1
• TMC278-TiDP6-C121: Drug-drug Interaction Trial to Investigate the Potential Interaction Between TMC278 25 mg Daily and Methadone, at Steady State.CompletedNCT00744770Phase 1
• TMC278-TiDP15-C150: Trial to Examine Safety, Tolerability and Plasma Pharmacokinetics of Multiple Doses of TMC278LA.TerminatedNCT00741741Phase 1
• TMC278-TiDP6-C136: Effect of TMC278 on Ethinylestradiol and Norethindrone in Healthy Women.CompletedNCT00739622Phase 1
• TMC278-TiDP6-C130: Pharmacokinetics, Safety and Tolerability of TMC278 in Subjects With Mildly or Moderately Impaired Hepatic Function.CompletedNCT00736905Phase 1

← Rilpivirine overview